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Abstract
Hepatoblastoma is the most common malignant pediatric liver
cancer. Histological evaluation of tumor biopsies is used to distin-
guish among the different subtypes of hepatoblastoma, with fetal
and embryonal representing the two main epithelial components.
With frequent CTNNB1 mutations, hepatoblastoma is a Wnt/b-
catenin-driven malignancy. Considering that Wnt activation has
been associated with tumor metabolic reprogramming, we charac-
terized the metabolic profile of cells from hepatoblastoma and
compared it to cells from hepatocellular carcinoma. First, we
demonstrated that glucose transporter GLUT3 is a direct TCF4/b-
catenin target gene. RNA sequencing enabled to identify molecular
and metabolic features specific to hepatoblastoma and revealed
that several glycolytic enzymes are overexpressed in embryonal-like
compared to fetal-like tumor cells. This led us to implement
successfully three biomarkers to distinguish embryonal from fetal
components by immunohistochemistry from a large panel of human
hepatoblastoma samples. Functional analyses demonstrated that
embryonal-like hepatoblastoma cells are highly glycolytic and sensi-
tive to hexokinase-1 silencing. Altogether, our findings reveal a new,
metabolic classification of human hepatoblastoma, with potential
future implications for patients’ diagnosis and treatment.
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Introduction
Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the
first and the second most common pediatric malignant liver tumors
representing about 1–2% of cancers in children. HB is detected in
very young children between the ages of 2 months and 3 years,
while HCC occurs most frequently in children between 10 and
16 years old and is the predominant type of adult liver cancer.
Fetal and embryonal HBs represent the two main epithelial
subtypes, together with small cell-undifferentiated, pleomorphic
poorly differentiated, cholangioblastic and epithelial macrotrabec-
ular patterns (Lopez-Terrada et al, 2014). Pure fetal with low
mitotic activity has the most favorable outcome and may be
treated by surgery alone (Czauderna et al, 2014). Components of
the Wnt/b-catenin pathway are frequently mutated and overac-
tive in solid malignancies promoting tumor development (Clevers
& Nusse, 2012). In HB, a driving proto-oncogene, and the most
recurrently mutated gene, with 50–90% frequency, is CTNNB1
that encodes b-catenin (Koch et al, 1999; Cairo et al, 2008;
Lopez-Terrada et al, 2009; Eichenmuller et al, 2014). CTNNB1
mutations in HB are located at exon 3, in a region of b-catenin
important for its degradation by the proteasome (Aberle et al,
1997). Hence, in-frame deletions or missense mutations within
exon 3 are gain-of-function mutations, resulting in a degradation-
resistant b-catenin protein that accumulates in the nucleus, binds
the TCF/LEF transcription factor, and drives the activation of
target genes. Interestingly, in HB, large deletions in CTNNB1,
which encompass exon 3 and part of exon 4, were reported exclu-
sively in pure fetal tumor histotypes, whereas CTNNB1 mutations
in embryonal HB are small mutations confined to exon 3 (Lopez-
Terrada et al, 2009). Although it is unclear whether and how dif-
ferent deletions affect b-catenin activity, the differential gene
expression profiles in HB subtypes raise the possibility of context
and time-dependent activation of b-catenin, leading to enriched
expression of Wnt and stem cell-related genes in embryonal
tumors, and activation of hepatic differentiation program in fetal
tumors (Cairo et al, 2008; Lopez-Terrada et al, 2009). Recently,
Wnt signaling was shown to increase glycolysis through the
upregulation of pyruvate dehydrogenase kinase 1 (PDK1) and
other glycolytic genes (Pate et al, 2014). This highlights an
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important contribution of the Wnt pathway for reprogramming
the cellular energetics of tumor cells.
It is becoming increasingly appreciated that different tumor types
exhibit different metabolic activities depending on the tissue of
origin and oncogenic mutations. Indeed, differences in glucose and
glutamine metabolism were recently uncovered between MYC- and
MET-induced liver tumors and between MYC-induced liver and lung
cancer (Yuneva et al, 2012). Hence, the identification of tumor
subtypes that differ metabolically could help to guide new diagnosis
and treatment approaches. In this study, we highlighted molecular
and metabolic differences between HB and HCC and characterized
the expression of metabolic genes in pediatric liver cancer. This led
us to define two different metabolic subtypes of HB with particular
diagnostic biomarkers.
Results
Molecular characterization of HB cell lines
In an effort to comprehend molecular differences between two
cancers that originate from the same tissue, HCC and HB, we pro-
filed four HCC (Huh-1, Hep3B, HLE, and HLF) and four HB (Hep-
U2, Huh-6, HepG2, and Hep293TT) cell lines using RNA sequencing
(RNAseq). Principal component and heatmap analysis showed that
the cell lines clustered by pairs (Fig 1A and B). Specifically, the two
most epithelial HCCs (Huh-1 and Hep3B), as defined by CDH1high,
VIMlow, and GLUT3low (Masin et al, 2014), clustered together, sepa-
rately from the two most mesenchymal ones (HLE and HLF), as
defined by CDH1low, VIMhigh, and GLUT3high, which clustered
together, too. Within the HB group, Huh-6 clustered with Hep-U2
and HepG2 with Hep293TT (Fig 1A). Gene expression analysis
revealed signatures of cytokine signaling enriched in the HCC group.
In contrast, the HB group was enriched for signatures of carbohy-
drate transport and metabolism (Fig 1C), suggesting HBs differ from
HCCs in sugar uptake and usage.
For this reason, we determined whether the differences between
the two groups of liver cancer cells (HCC and HB) could be associ-
ated with different utilization of genes involved in glucose metabo-
lism. We found a strong enrichment for glucose transporter
expression in HB cells (Fig 1D). Among them, GLUT3 was robustly
expressed in HBs compared to HCCs, with Huh-6 and Hep-U2
exhibiting the highest levels (Figs 1D and 2A, and Dataset EV1). We
recently reported that SLC2A3 encoding for GLUT3 is induced by
ZEB1 during epithelial–mesenchymal transition (EMT) in tumor
cells from non-small cell lung cancer (NSCLC) and HCC (Masin
et al, 2014). However, when we compared HLE, a mesenchymal
HCC cell line (Masin et al, 2014), with our panel of four cell lines
derived from human HB, GLUT3 expression was stronger in each of
the HB cells (Fig 2A). Unfortunately, we could not maintain Hep-U2
in culture so our data on this cell line is limited to gene expression
analysis. Immunocytochemistry (ICC) confirmed the strongest
GLUT3 protein expression and membrane localization in Huh-6,
followed by HepG2, Hep293TT, and HLE (Fig 2B). Huh-1, an epithe-
lial HCC cell line, was negative. We then decided to explore whether
this difference in GLUT3 expression is linked to a differential
glucose uptake and utilization in the seven tumor cell lines. First,
we monitored glucose uptake and found Huh-6 displaying a very
high glucose consumption compared to every other cells (Fig 2C).
We further explored whether this difference in glucose uptake may
have consequences on the metabolic program of the different cells.
Glycolysis and oxidation were determined through measurements of
the extracellular acidification rate (ECAR) and oxygen consumption
rate (OCR), respectively. The HB cell lines displayed a high oxida-
tive and a low glycolytic profile (Fig 2D). Importantly, Huh-6 cells
had a particular profile within HB, with a strong glycolytic metabo-
lism (Fig 2D). The Huh-6 glycolytic profile was further confirmed
using an independent assay based on the oxidative activity of mito-
chondria, showing the high glycolytic rate of those cells compared
to all other cell lines (Fig 2E). To better characterize the glycolytic
potential of the different cell lines, we performed sequential addition
of glucose and 2-deoxyglucose (DG) after 24-h glucose starvation.
As a result, we found that Huh-6 exhibited the highest glucose
response in comparison with all other tested cell lines (Fig 2F).
Interestingly, we also observed a response to glucose in Hep293TT
confirming the glycolytic potential of these cells that we previously
found with MitoTracker (Fig 2E). In contrast, we did not observe a
clear response to glucose in the other tested cell lines. To under-
stand the different metabolic profiles within HBs, we tested whether
the less glycolytic cells, HepG2 and to a lesser extent Hep293TT,
may have a higher fatty acid (FA) oxidation capacity. We measured
OCR after addition of palmitate–BSA or BSA alone (vehicle control)
after 24 h in limited medium (no glucose, 1% FBS). Only HepG2
consumed palmitate, while there was no response for Huh-6
(Fig 2G). A trend for increased consumption in Hep293TT was also
detected, although this did not reach significance. Hence, decreased
glucose use indeed correlates with increased FA use in HB cells. To
understand better the molecular basis for FA consumption in the dif-
ferent cell lines, we took advantage of our RNAseq data to monitor
the expression of CPT1A (carnitine palmitoyltransferase 1A),
responsible for exogenous fatty acid incorporation into mitochon-
dria. This gene was expressed in fetal-like cells with HepG2
▸Figure 1. Gene profiling reveals enhanced carbohydrate uptake and metabolism in tumor cells from HB compared to HCC.A Multidimensional scaling (MDS) plot of the expression levels derived from the RNAseq. Distance between sample labels indicates similarity. Samples form four distinct
groups according to the four cell line types.
B Heatmap of the enrichment scores from the single-sample GSEA. Each column of the heatmap shows a cell line, while the rows represent gene sets. The plotted gene
sets are the top 50 differentially enriched sets in HCC versus HB cell lines ranked by FDR. Color scale in the heatmap represents scores standardized across rows.
C Heatmap of the enrichment scores from the single-sample GSEA. Each column of the heatmap shows a cell line, while the rows represent gene sets. The plotted gene
sets are those that have been found as significantly enriched or depleted in HCC versus HB cell lines at a false discovery ratio (FDR) < 0.05. Differential enrichment is
assessed on the ssGSEA enrichment scores with the limma package. Color scale in the heatmap represents scores standardized across rows.
D Expression levels from RNAseq of the different glucose transporters differentially expressed in all HB compared to all HCC cell lines. Data show means  s.d. (n = 4).
P-values were determined by Mann–Whitney test.
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displaying the strongest expression (Datasets EV1 and EV2), but
was almost not expressed in embryonal-like Huh-6. In order to
explore more precisely FA metabolism in the different HB cell
subtypes, we used Etomoxir, a CPT1A inhibitor, which blocks
exogenous fatty acid consumption. Only HepG2 oxygen consump-
tion was affected by Etomoxir, revealing the highest exogenous fatty
acid dependence in this cell type (Fig 2H).
To characterize the specific profile of Huh-6 within HBs, we
examined broadly genes of glucose metabolism whose expression
is, like that of GLUT3, significantly different between Huh-6 and the
other HB cell lines. In total, we found nine differentially expressed
genes implicated in glycolysis or the reverse biological process,
gluconeogenesis. Specifically, in addition to GLUT3, three genes
coding for enzymes of glycolysis, HK1 (coding for hexokinase 1),
PFKP (phosphofructokinase, platelet type), and LDHB (lactate dehy-
drogenase B), were significantly more elevated in Huh-6. In
contrast, genes promoting gluconeogenesis, PPARGC1A (PGC-1a),
an important liver gluconeogenesis transcriptional co-activator
(Herzig et al, 2001; Yoon et al, 2001), AQP9 (aquaporin-9), GK
(glycerol kinase), and G6PC (glucose-6-phosphatase), were all less
abundant in Huh-6 and Hep-U2 (Fig 3A, Appendix Fig S1A, Datasets
EV1 and EV2), supporting the increased glycolysis of these cells
compared to other HB cells. As notable exception, HepG2 and
Hep293TT cells expressed HK2 to a significantly higher level than
Huh-6 and Hep-U2. This is interesting, as HK2 is often overex-
pressed in adult solid tumors (Patra et al, 2013; Guo et al, 2015),
which is compatible with a more differentiated state of those cells,
while HK1 expression is strong specifically in the developing mouse
liver (Appendix Fig S1B).
Because of the singularity of Huh-6 cells within HBs for utiliza-
tion of glucose and because HB is a b-catenin-driven cancer, we
wanted to know whether the Huh-6 cell line could represent a dif-
ferent subtype of HB at the molecular level. Western blotting of b-
catenin, frequently mutated in HBs, with an antibody recognizing
the C-terminus, revealed two bands for HepG2 and Hep293TT, but
only one for the other liver tumor cells including Huh-6 (Fig 3B). In
contrast, a second antibody recognizing the N-terminus failed to
detect the shortest form specific to HepG2 and Hep293TT, suggest-
ing this variant lacks some amino acids located near the N-terminus
(Fig 3B). Because HepG2 is known to carry a large CTNNB1 deletion
of exon 3 and part of exon 4, and Huh-6 a point mutation within
exon 3 (Koch et al, 1999), we hypothesized that Hep293TT carries a
similar deletion than HepG2. To identify the exact CTNNB1 muta-
tions, we analyzed the exon coverage profile using the RNAseq
reads. This revealed that (i) Huh-6 has a GGA to GTA point muta-
tion at codon 34, resulting in a G to V amino acid substitution, (ii)
Hep-U2 carries a small deletion confined to exon 3, and (iii) both
HepG2 and Hep293TT have a large deletion, typical of fetal HB
subtypes, encompassing exon 3 and part of exon 4 (Fig 3C). PCR-
based genomic amplification confirmed the genomic deletions
(Fig EV1A). Mutations in Hep-U2 and Huh-6 are reminiscent of
embryonal HB. Additionally, real-time PCR and ICC showed a
stronger expression of LIN28A, expressed in undifferentiated tissues
and important for embryonic stem cells (Tan et al, 2014), in Huh-6
and Hep-U2 compared to HepG2 and Hep293TT. In contrast,
CLDN1, which codes for claudin-1, a tight junction protein enriched
in the fetal compared to the embryonal components of HB (Halasz
et al, 2006), was more elevated in HepG2 and Hep293TT
(Fig EV1B–D and Dataset EV1). Finally, we analyzed the top 200 dif-
ferentially expressed genes between the two cell clusters using Gene
Ontology (http://geneontology.org/). This revealed biological
processes of development, morphogenesis, and embryogenesis from
the genes up in Huh-6 and Hep-U2, compatible with a block in early
development or undifferentiated stage. In contrast, the same analy-
sis highlighted metabolic processes from the genes up in HepG2 and
Hep293TT, reminiscent of the physiological function of differenti-
ated hepatocytes (Datasets EV3 and EV4). Hence, Hep-U2 and
Huh-6 classify as poorly differentiated embryonal-like HB, whereas
HepG2 and Hep293TT represent more differentiated, fetal-like HB.
We then explored the impact of GLUT3 in the different cell
lines with GLUT3 siRNA, which strongly decreased its expression
(~80% decrease) (Fig 3D). Using this approach, we first found
that GLUT3 was essential for glucose uptake (Fig 3E) in Huh-6
but not in HepG2. Second, we performed a glycolysis assay using
seahorse. Huh-6 glycolytic capacity was altered by the reduction
of GLUT3 while HepG2 was insensitive to GLUT3 decrease
(Fig 3F). Finally, Hep293TT exhibited an intermediate response in
absence of GLUT3 correlating well with their partial glycolytic
phenotype observed with MitoTracker and seahorse experiments
(Fig 2E and F).
In order to test the validity of our cell line-based classification in
human samples, we used immunohistochemistry and stained 20
▸Figure 2. Identification of two HB metabolic subtypes.A Expression of GLUT3 in the different cell lines. Data show means  s.d. (n = 3). P-values were determined by Mann–Whitney test.
B Immunocytochemistry of GLUT3 on the indicated cell lines. Dashed squares highlight a zoom on a cell. Scale bar: 20 lm.
C 2-Deoxy-d-[3H]glucose (DG) incorporation was measured in the indicated HB cell lines. Data show means  s.d. (n = 5) of glucose uptake (nmol) normalized to
protein concentration. Huh-6 values were significantly different (*P < 0.05, Mann–Whitney test) to each other cell lines. The highest P-value is indicated.
D Seahorse analysis of lactate production (ECAR) and oxygen consumption (OCR) in HB cell lines. Analysis was done on 10 measurements per sample and was
performed 3 times. Data show means  s.d. P-values were determined by Mann–Whitney test.
E Flow cytometry analysis of the oxidative state (oxy) with MitoTracker Red (MTRed) and Green (MTGreen). Data are normalized to total mitochondrial mass (MTRed/
MTGreen). Glycolytic state (gly) was calculated as 1 – (MTRed/MTGreen). Huh-6 values were significantly different (****P < 0.0001) to each other cell lines. Data show
means  s.d. (n = 5). P-values were determined by Mann–Whitney test.
F After 24 h of glucose starvation, 10 mM glucose was added to the wells followed by 2-DG to block glycolysis at a concentration of 50 mM. Sequential measurements
of ECAR from 10 replicates after the injections were done. Data show means s.e.m.
G After 24 h in limited medium, BSA-palmitate or BSA was added just before seahorse experiment; 5 sequential measurements of OCR from 10 replicates were done.
Data show means  s.d. P-values were determined by Mann–Whitney test.
H After 24 h in limited medium, BSA-palmitate or BSA was added just before seahorse experiment in presence or in absence of 10 mM Etomoxir. Five sequential
measurements of OCR from 10 replicates were done. Data show means  s.d. P-values were determined by Mann–Whitney test.
EMBO Molecular Medicine Vol 9 | No 11 | 2017 ª 2017 The Authors
EMBO Molecular Medicine Metabolic diversity in hepatoblastoma Stefania Crippa et al
1592
Published online: September 18, 2017 
0.0 0.5 1.0
Huh-6
HepG2
Hep293TT
Huh-1
Hep3B
HLE
MTRed/  MTGreen
oxy
gly
****
*
**
H
ep
G
2
H
ep
29
3T
T
H
uh
-6
He
p3
B
H
uh
-1
HL
E
H
LF
0
200
400
600
*
R
el
.  
Ex
pr
es
sio
n/
HL
E
B
Huh-6 HepG2 Hep293TT
GLUT3
HLE Huh-1
****
0
100
200
300
GLUT3
A
E
H
ep
G
2
H
ep
29
3T
T
H
uh
-6
H
uh
-1
H
LE H
LF
Al
l H
B
Al
l H
CC
0
10
20
30
40
50
EC
AR
 
(m
pH
/m
in
)/p
ro
te
in
 
(µg
/µ
l) ****
****
*
p= 0.0001
p< 0.0001
p< 0.0001
p< 0.0001
p< 0.0116
p< 0.0001
p< 0.0001
p< 0.0001
p= 0.0108
p=0..0.0108
p< 0..0001
p< 0..0001
H
ep
G
2
H
ep
29
3T
T
H
uh
-6
H
uh
-1
HL
E
H
LF
Al
l H
B
Al
l H
CC
0
50
100
150
200
OC
R
 
(pM
ol
e
s/m
in
)/p
ro
te
in
 
(µg
/µ
l)
****
**
***
p< 0.00 1
p= 0.0007
p= 0.0035
p= 0.0035
p= 0.0159
****
****
***
C
D
G
0 10 20 30 40 50 60 70 80 90 10
0
11
0
12
0
0
10
20
30
40
50
EC
AR
 
(m
pH
/m
in
)/p
ro
te
in
 
(µg
/µ
l)
Hep293TT
HepG2
Huh-6
Huh-1
HLF
Glucose 2-DG
0
10
20
30
40
OC
R
 
(pM
ol
e
s/m
in
)/p
ro
te
in
 
( µg
/ µ
l)
Huh6 HepG2 Hep293TT
*
+ Etomoxir
 - Etomoxir
H
F
0
10
20
30
40
50
OC
R 
(pM
o
le
s/m
in
)/p
ro
te
in
 (µ
g/
µl
)
Huh-6 HepG2 Hep293TT
****
BSA-Palmitate
BSA
2-
D
G
 tr
an
sp
or
t 
(nm
ol/
mg
 pr
ot*
10
 m
in)
H
ep
G
2
H
ep
29
3T
T
H
uh
-6
H
ep
3B
H
uh
-1
H
LE H
LF
H
ep
G
2
H
ep
29
3T
T
H
uh
-6
H
uh
-1
H
LE H
LF
Al
l H
B
Al
l H
CC
H
ep
G
2
H
ep
29
3T
T
H
uh
-6
H
uh
-1
H
LE H
LF
Al
l H
B
Al
l H
CCE
CA
R 
(m
pH
/m
in)
/pr
ote
in 
(μg
/μ
l)
O
CR
 (p
Mo
les
/m
in)
/pr
ote
in 
( μg
/μ
l)
HepG
Hep293T
Huh-
Hep3
Huh-
HL
p= 0.0369
p< 0.0001
EC
AR
 (m
pH
/m
in)
/pr
ote
in 
( μg
/μ
l)
Hep
Hep
Huh-
Huh-
HLF
Figure 2.
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 11 | 2017
Stefania Crippa et al Metabolic diversity in hepatoblastoma EMBO Molecular Medicine
1593
Published online: September 18, 2017 
C175
80
175
80
55
116
β-catenin
(C-term)
β-catenin
(N-term)
Tubulin
PARP
nuclear
B
PPARGC1A 
**
0
4
8
12
16
0
100
200
300
400
500
0
5000
10000
15000
20000
BHDLPKFP1KH
*
***
*
** *** **
HK2
0
1
2
3
R
el
. e
xp
re
ss
io
n/
He
p2
93
TT
AQP9 GK
0
1
2
0
1
2
3
4
5
0
2
4
6
8
10
0
3
6
9
12
15 G6PC 
**
*
*
*
**
**
**
**
**
A
p= 0.036
p= 0.004
p= 0.025
p= 0.0016 p= 0.0002p= 0.001
p= 0.002p= 0.0339
p= 0.012
p= 0.02 p= 0.002
p= 0.006
p= 0.007
p = 0.0111
F
cytoplasmic
Hep293TT
HepG2
0 10 20 30 40 50 60 70 80 90 10
0
11
0
12
0
13
0
0
20
40
60
**
EC
AR
 
(m
pH
/m
in
)/p
ro
te
in
 (µ
g/
µl
)
Glucose 2-DG
p= 0.000368p< 0.0001
0 10 20 30 40 50 60 70 80 90 10
0
11
0
12
0
13
0
0
20
40
60
*
EC
AR
 
(m
pH
/m
in
)/p
ro
te
in
 
(µg
/µ
l)
0
200
400
600
800
1000 *
Huh-6 HepG2
siCtrl
siGLUT3
0.0
0.5
1.0
1.5
Huh-6 Hep293TT HepG2
*** * **
Glut3 
siCtrl
siGLUT3
E
p= 0.0003 p= 0.0164 p= 0.0093
Glucose 2-DG
p= 0.0034
0 10 20 30 40 50 60 70 80 90 10
0
11
0
12
0
13
0
0
10
20
30
40
EC
AR
 (m
pH
/m
in
)/p
ro
te
in
 (µ
g/
µl
)
Glucose 2-DG
siCtrl
siGLUT3 
Huh-6
D
**
P< 0.01
P< 0.01
GK
GLUT3
EC
AR
 (m
pH
/m
in)
/pr
ote
in 
(μ g
/μ
l)
EC
AR
 (m
pH
/m
in)
/pr
ote
in 
(μg
/μ
l)
EC
AR
 (m
pH
/m
in)
/pr
ote
in 
(μg
/μ
l)
re
la
tiv
e 
ex
pr
es
sio
n
2-
D
G
 tr
an
sp
or
t (n
mo
l/
m
g 
pr
ot
*1
0 
m
in
)
p= 0.007
Figure 3.
EMBO Molecular Medicine Vol 9 | No 11 | 2017 ª 2017 The Authors
EMBO Molecular Medicine Metabolic diversity in hepatoblastoma Stefania Crippa et al
1594
Published online: September 18, 2017 
post-chemotherapy HB surgical specimens, which have been histo-
logically classified and scored for their embryonal/fetal status by
two pathologists (CG and ALR) using standard H&E or HPS staining
(Dataset EV5). Because we identify GLUT3 as strongly expressed in
embryonal-like cells, we assessed the ability of GLUT3 staining to
distinguish embryonal and fetal tumors. While staining for GLUT3
was never observed in healthy liver, in tumor samples GLUT3 was
exclusively expressed in a minority of the cells from embryonal foci
(mild 1+ cytoplasmic reactivity, and mild 1+ or moderate 2+
membranous staining in 5/13 cases), or from the squamous compo-
nent (mild 1+ or moderate 2+ staining in all three cases) (Figs 4A–C
and EV2A–F). The latter finding prompted us to assess CK5/6 reac-
tivity, a squamous epithelium and basal cell marker, in all HB cases
displaying a histologically obvious squamous component, and/or
reactivity to GLUT3. As expected, foci of squamous differentiation
were reactive to CK5/6. Moreover, in one of four HBs with no obvi-
ous squamous differentiation, CK5/6 highlighted a basal-like cell
component in areas reactive to GLUT3 (Fig EV2D–F). Importantly,
the fetal cells did not stain for GLUT3 in any of the HBs with a fetal
component (Fig 4A and C). Chemotherapy causes a decrease in
GLUT3 expression (Watanabe et al, 2010), (Fig EV2G), suggesting
GLUT3 expression is underestimated in post-chemotherapy HB
samples. Thus, GLUT3 is a marker able to distinguish embryonal
from fetal tumors.
GLUT3 is a target gene of the Wnt/b-catenin pathway
Because HB is a b-catenin-driven malignancy, with c-Myc and YAP
also contributing to disease development (Shachaf et al, 2004; Tao
et al, 2014; Lehmann et al, 2016), we hypothesized one of them to
be implicated in the sugar metabolic phenotype observed in HB cell
lines. To test this possibility, we transfected Hep293TT, HepG2, and
Huh-6 with a control siRNA, or with siRNAs targeting CTNNB1 or
MYC. CTNNB1 but not MYC silencing resulted in a significant
decrease in GLUT3 mRNA (Fig 5A and Appendix Fig S1C). The
expression of other glycolytic genes remained unchanged or
increased upon transfection with siRNA targeting CTNNB1
(Appendix Fig S2A). In a similar way, we assessed the potential role
for YAP in GLUT3 regulation by both overexpression and silencing.
We did not observe a strong impact of YAP alteration on GLUT3
expression reinforcing the specific role of b-catenin in GLUT3 regu-
lation (Appendix Fig S2B and C). We decided to investigate further
the link between b-catenin and GLUT3. First, we used two reporter
constructs previously generated (Masin et al, 2014) of the promoter
or the second intron of GLUT3 placed before a minimal promoter
driving luciferase expression. b-Catenin overexpression led to an
increase in the luciferase activity of the intron 2 but not the
promoter construct (Fig 5B). To identify the region within this
intron responsive to b-catenin, we generated four deletion
constructs (F1-F4), and only F4 was induced (Fig 5C). We further
divided F4 into F4a-c, which revealed that F4c was the most
responsive to b-catenin (Fig 5D). Interestingly, a TCF4-binding site
was predicted within this fragment (http://jaspar.genereg.net/)
(Fig 5E), suggesting b-catenin acts as co-activator for the TCF/LEF
transcription factor to stimulate GLUT3 transcription; deletion of
this sequence abolished the b-catenin-mediated increased luciferase
activity (Fig 5E). To identify whether the Wnt/b-catenin signaling
pathway directly promotes GLUT3 gene induction, we performed
chromatin immunoprecipitation (ChIP) on TCF4 and b-catenin
followed by real-time PCR. As negative control, we used a region
in Myc 50UTR unresponsive to the Wnt/b-catenin (Bottomly et al,
2010). These results revealed a binding of TCF4, as well as
b-catenin (most likely through TCF4), to the GLUT3 intron 2, frag-
ment F4, but not to F1, or to the promoter region (Fig 5F and
Appendix Fig S3A and B). Interestingly, b-catenin binding was
stronger in Huh-6. These findings suggest a link between the
b-catenin different mutations and its ability to induce GLUT3,
which may in turn be responsible for the strong glycolytic capabil-
ity we observed in Huh-6.
Long b-catenin deletion mutants do not interact with a-catenin
Because of the correlation between b-catenin mutation and GLUT3
binding, we investigated implications of the different CTNNB1 muta-
tions in fetal and embryonal HB cell lines. We found that genes
associated with the canonical Wnt pathway are more expressed in
the embryonal-like than the fetal-like HB cell lines (Dataset EV3).
We reasoned that the extent of CTNNB1 deletion could cause a loss
of interaction with specific co-activators of Wnt-target genes. We
first evaluated whether in fetal-like HB cell lines, the partial deletion
of CTNNB1 exon 4 could alter the capability of b-catenin to interact
with BCL9 and BCL9L, which are established co-activators of the
Wnt pathway important to specify a stem cell-like phenotype in
cancer cells (Brembeck et al, 2004; Deka et al, 2010). We found that
co-inhibition of BCL9-BCL9L only faintly reduced the expression of
GLUT3 in Huh-6 (Appendix Fig S4A) and we did not observe a
stronger luciferase activity of GLUT3 intron 2 upon transient overex-
pression of BLC9L together with b-catenin (Appendix Fig S4B). In
agreement with this, the alpha-helix responsible for BCL9-BCL9L
binding (Sampietro et al, 2006) is still present in the long deletion
form of b-catenin. In marked contrast, we modeled that the residues
encoded by exon 4 that are missing in fetal b-catenin mutants are
◀ Figure 3. The glycolytic profile of HB cell lines is correlated to b-catenin mutation.A Real-time PCR using specific probes for glycolytic (HK1, PFKP, LDHB, HK2) and gluconeogenesis (AQP9, GK, G6PC, PPARGC1A) genes. Data show means  s.d. (n = 3).
P-values were determined by Mann–Whitney test.
B Cytoplasmic and nuclear protein extracts isolated from the indicated cell lines were analyzed for b-catenin expression by Western blot.
C Histograms of the RNAseq read counts for the CTNNB1 region in the embryonal and fetal cell lines.
D Real-time PCR on GLUT3 after siGLUT3 or siCtrl transfection. Data show means  s.d. (n = 3). P-values were determined by Mann–Whitney test.
E Glucose uptake assay in HepG2 and Huh-6 after transfection with siGLUT3 or siCtrl. Data show means  s.d. (n = 5). P-values were determined by Mann–Whitney
test.
F Seahorse glycolytic assay on the three hepatoblastoma cell lines after transfection with siGLUT3 or siCtrl. Sequential measurements of ECAR from 10 replicates after
the injections were done. Data show means  s.d. Multiple t-test was used.
Source data are available online for this figure.
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Figure 4. The embryonal component of human HB tumors stains positive for GLUT3.
A Representative H&E or GLUT3 staining of human HB tumor sections. Scale bars: 200 lm (original magnification ×40).
B Representative GLUT3 IHC staining of two human HB tumor sections at high magnification showing the embryonal component positive for GLUT3 expression. Stars:
fetal component; arrows: embryonal component. Scale bars: 100 lm (original magnification ×100).
C Contingency table between the absence/presence of the staining and the embryonal/fetal status. Chi-square test was used.
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Figure 5. GLUT3 is a direct target of TCF4/b-catenin.
A Real-time PCR analysis for CTNNB1, MYC, and GLUT3 expression in HB cell lines after siRNA transfection. Data show means  s.d. (n = 3). P-values were determined
by Mann–Whitney test.
B The promoter region (P) and the intron 2 (I2) of GLUT3 were cloned into a luciferase reporter and measured as relative light unit (RLU) from HEK 293T cells
transfected with the luciferase reporter and b-catenin expressing vector or an empty vector as negative control.
C Luciferase activity was measured as in (B) with GLUT3 intron 2 separated into four different fragments.
D Luciferase activity was measured as in (B) with GLUT3 intron 2F4 divided into three fragments.
E Luciferase activity was measured as in (B). For I2, F4, and F4c, either wild-type or a variant with a deletion of the TCF4 binding site (DTCF4) was used.
F Chromatin extract from the indicated cell lines was used for TCF4 (upper panel) or b-catenin (lower panel) ChIP-real-time PCR. A 5-kb region upstream of the MYC
gene (50 Myc) was used as negative control. Experiments were performed in triplicates per each condition and analyzed separately. See Appendix Fig S3A and B.
Data information: For (B–E), data show means  s.d. (n = 5) and P-values were determined by Mann–Whitney test.
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involved in interaction with a-catenin (Fig EV3A). To prove that
fetal-type b-catenin long deletion mutants have lost their ability to
interact with a-catenin, we performed co-immunoprecipitation
experiments. Of the four VSV-tagged b-catenin constructs (repre-
senting each mutant from the four HB cell lines), FLAG-tagged
a-catenin interacted with the Huh-6 and the Hep-U2-derived
mutants, but none of the HepG2 or Hep293TT ones (Fig EV3B).
Additionally, in fetal-like HB cells, only wild-type endogenous
b-catenin, not the fetal Dex3-4 mutants despite strong expression,
bound endogenous a-catenin (Fig EV3C). For Huh-6 cells, although
there was a clear interaction, it was not possible to know which of
wild-type, the point mutant, or both b-catenin proteins were
involved. Hence, our results demonstrate that fetal-specific HB b-
catenin (Dex3-4) mutants are unable to bind a-catenin.
Different HB subtypes are sensitive to specific
glycolysis inhibitors
In order to determine whether the specific embryonal-like cell
metabolism can be exploited to reduce proliferation and survival
we decided to interrogate the dependency on glycolysis. We used
two compounds: 2-DG and 3-bromopyruvate (3BP). 2-DG is phos-
phorylated by hexokinase but not metabolized further, whereas
3BP inhibits HK2 (Pedersen, 2012; Shoshan, 2012). Strikingly,
apoptosis was triggered in Huh-6 cells submitted to 2-DG, which
was already visible with 25% of 2-DG, as indicated by Annexin-V
positivity and by an increased caspase-3/7 activity (Fig 6A and B,
Appendix Fig S5A and B). In contrast, HepG2 cells did not respond
to 2-DG incubation, whereas Hep293TT showed only an intermedi-
ary response. We confirmed the strongest Huh-6 response by
monitoring ATP production after 2-DG treatment in the three cell
lines (Appendix Fig S5C).
In marked contrast, 3BP affected fetal-like cells preferentially,
as indicated by the increase in Annexin-V staining and caspase-3/7
activity observed in HepG2 and Hep293TT compared to Huh-6
(Fig 6C, Appendix Fig S5D and E) and by the reduced production
of ATP in fetal compared to embryonal-like HB cells (Fig 6D).
These data support the known HK2 inhibitory effects of 3BP and
are consistent with more expressed HK2 in fetal-like cells. We next
tested the possibility of an HK-isoform-specific dependency for the
two groups of HB. Congruent with strong HK1 levels in Huh-6,
siRNA-mediated HK1 but not HK2 gene silencing led to an
increased cell death as revealed by Annexin-V staining. In contrast,
HepG2 and Hep293TT were affected by HK2 but not HK1 silencing
(Fig 6E and F). Altogether, our results demonstrate that embry-
onal-like cells differ from fetal-like cells with a distinct metabolic
dependency with different sensitivity to glycolysis inhibitors and
that the survival of the two HB subtypes relies on different HK
isoforms.
LDHB and G6PC stain different human HB components
In an effort to validate our metabolic subtypes in vivo and in order
to identify new diagnostic biomarkers in addition to GLUT3, we
characterized the expression of LDHB and G6PC, whose coding
genes were differentially expressed in embryonal compared to fetal-
like HB cell lines (see Fig 3A, Datasets EV1 and EV2). In non-tumor
liver, LDHB was moderately expressed in the cytoplasm and nucleus
of interlobular bile duct cells, but never in hepatocytes. As expected,
G6PC showed moderate cytoplasmic staining of the non-tumor
hepatocytes while cholangiocytes remained negative.
In the fetal component, tumor cells showed a diffuse reactivity to
G6PC, with the exception of two tumors characterized by focal
staining (Fig 7A, B and J). Reactivity ranged from mild (1+) to
strong (3+), and the pattern of staining was mainly cytoplasmic. On
the other hand, 16 out of 30 fetal tumors were negative for LDHB
expression, with only a slight reactivity along the sinusoids (Fig 7C
and K). In contrast, the vast majority of tumors displaying embry-
onal differentiation (21/23) expressed LDHB (Fig 7D, F and K). Of
note, LDHB even revealed small foci of cells with a high nuclear
cytoplasmic ratio consistent with embryonal cells, which had not
been detected on standard H&E or HPS (Fig 7I). The embryonal foci
of HB tumors remained negative for G6PC staining in nearly 50% of
the cases (12/22) (Fig 7E and J). In one embryonal tumor positive
for G6PC, cells tended to be larger and more mature appearing
(Fig 7G and H).
These analyses from primary tumors confirmed our in vitro find-
ings and collectively reveal that embryonal and fetal HBs, which
represent two distinct histological components of HB, could be
metabolically classified based on the expression of LDHB and G6PC,
markers of glycolysis and gluconeogenesis. Based on our results,
GLUT3 as well as LDHB and G6PC staining could serve as novel
diagnostic tools in addition to histological classification to guide HB
diagnosis, highlighting in some instances minor cell components
not readily identified on routine standard stains.
Discussion
In this study, we performed a transcriptome profile to investigate
the molecular differences between adult HCC and pediatric HB,
which led us to identify an enhanced sugar transport and usage in
HB tumors. Moreover, we were able to identify two different meta-
bolic subtypes of HB based on the type of glucose metabolism, with
the embryonal-like cells displaying increased glycolysis and the
fetal-like expressing stronger levels of gluconeogenesis genes. We
also described a novel role for b-catenin in the regulation of glucose
transporter GLUT3 expression. This allowed the discovery of three
new robust biomarkers to distinguish between the different HB
subtypes.
Although a majority of tumors harbor mutations in CTNNB1,
long deletions encompassing exons 3 and 4 are only detected in
pure fetal HB, and correlate with increased Notch versus Wnt path-
way activation (Lopez-Terrada et al, 2009). Conversely, embryonal
HBs express small deletions or missense mutations in CTNNB1 and
show Wnt over Notch activation. These findings are compatible
with tumorigenesis taking place in the context of early differentia-
tion stage during liver development for embryonal HB, and later
stage for fetal HB. Our identification of increased expression of
gluconeogenesis-related genes in fetal-like HB cells also reflects their
increased differentiation, closer to mature hepatocytes. By exten-
sion, this intricate connection between organogenesis and tumorige-
nesis is particularly relevant for pediatric solid malignancies, where
tumorigenesis arises within developmentally immature tissue envi-
ronments (Scotting et al, 2005). A recent gene expression profiling
has enabled a molecular classification of HB, revealing two groups
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Figure 6. The two groups of HB cell lines are sensitive to different inhibitors of glycolysis and use different hexokinases.
A Analysis of Annexin V staining 24 h after 2-DG treatment. The indicated cell lines were stained with Annexin V–APC antibody. Data show means  s.d. (n = 3).
B Analysis of caspase-3/7 activity in the indicated cell lines cultured in presence of 2-DG compared to control. Experiments were performed in triplicates per each
condition and analyzed separately. Data show one representative replicate out of three independent experiments (see Appendix Fig S5A and B for the other replicates).
C The indicated cell lines were stained with Annexin V 12 h after treatment with 3BP to estimate the percentage of viable (V) early (EA), late (LA) apoptotic, and necrotic
(N) cells. Data show means  s.d. (n = 3).
D ATP production was measured in the indicated cell lines 12 h after 3BP treatment. Data show means  s.d. (n = 3).
E The indicated cell lines were transfected with HK1, HK2, or control siRNA. HK1 and HK2 expressions were analyzed by real-time PCR. Data show means  s.d. (n = 3).
F The indicated cell lines were stained with Annexin V–APC antibody 72 h after transfection with HK1 siRNA, HK2 siRNA, or control siRNA. Data show means  s.d.
(n = 4).
Data information: P-values were determined by Mann–Whitney test. For (A–D), normal medium was used as control.
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Figure 7. LDHB and G6PC stain different components of human HB tumors.
A–C Fetal component. On the right-hand side, irregular distribution of glycogen imparts a “light” pattern on HPS (A), and perinuclear “clumped” G6PC accumulation (B).
The fetal tumor cells do not react to LDHB (C). Instead, LDHB reactivity is observed along the sinusoids.
D–I Embryonal component. Tumors displaying embryonal differentiation expressed LDHB (F). LDHB further highlights small foci of cells with a high nuclear cytoplasmic
ratio consistent with embryonal cells (I). The embryonal tumor cells remained negative for G6PC (E). Only one tumor (G) with embryonal cells that tended to
appear larger and more mature showed focal G6PC reactivity (H). Arrows: embryonal component; stars: fetal component. Scale bars: 100 lm (original magnification
×200), except for (C), scale bar: 50 lm (original magnification ×400).
J, K Contingency table of G6PC and LDHB staining depending on the embryonal/fetal status of the tumor. Chi-square test was used.
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evoking distinct phases of liver development. One of them, called
C2, was enriched for embryonal tumors, expressed hepatic stem/
progenitor markers of immature liver, and was associated with bad
prognosis (Cairo et al, 2008). Interestingly, gene expression from C2
tumors clustered with that of early liver development in the mouse
(E11.5 and 12.5). HK1, which we found overexpressed in embryonal
compared to fetal-like tumor cells, is abundant in the developing
liver, with levels dramatically reduced at birth. In contrast, HK2,
whose expression is low in developing and adult liver, is the most
commonly upregulated hexokinase isoform in adult tumors. This
reveals alternative strategies in hexokinase utilization, adult tumors
and fetal HB expressing mostly HK2, embryonal HBs relying on the
embryonic isoform, HK1. This may open therapeutic opportunities,
as this knowledge could enable the future development of isoform-
specific hexokinase small molecule inhibitory compounds. Simi-
larly, our study reveals that a possible target of aggressive HB would
be GLUT3 itself. The development of molecules transported into
tumor cells through GLUT3 to deliver toxic compounds or to block
glucose transport activity might be facilitated by the recent X-ray
crystal structure determination of this transporter and other
members of this family, GLUT1 and GLUT5 (Deng et al, 2014, 2015;
Nomura et al, 2015).
The modulation of GLUT3 levels in cancer appears to depend
on the activity of various factors. Indeed, in tumor cells from
colorectal cancer, GLUT3 was induced by caveolin-1, in a HMGA1-
dependent manner, HMGA1 enhancing GLUT3 transcription by
binding to specific sites within its promoter region (Ha et al,
2012). In cells derived from NSCLC or HCC, GLUT3 was induced in
response to ZEB1 activity during EMT (Masin et al, 2014), and
GLUT3 is known to respond to NF-jB (Kawauchi et al, 2008). In
this study, we found that GLUT3 is a direct target gene of TCF4/b-
catenin in tumor cells from HB. TCF4/b-catenin binding in the
GLUT3 gene occurs at the end of intron 2, in the same intron, and
only ~250 bp after the ZEB1 binding site (Masin et al, 2014),
demonstrating a central regulatory role for this intragenic enhancer
in cancer cells.
We showed that mutant b-catenin interacts with a-catenin
exclusively in HB cells with alterations confined to CTNNB1 exon
3, larger deletions spanning exon 3 to 4 found in fetal HB tumors,
HepG2 and Hep293TT preventing binding. a-Catenin plays a criti-
cal role in cell–cell junction (Nelson & Nusse, 2004) and in regu-
lation of gene transcription (Choi et al, 2013; Daugherty et al,
2014; McCrea & Gottardi, 2016). Considering this, it will be
important to delineate the contribution of the b-catenin/a-catenin
complex in fine-tuning the Wnt-dependent transcriptional
program and/or metabolic reprogramming in embryonal versus
fetal HB tumors.
A limitation of our study is the lack of animal models. To study
HB, a limited number of genetically engineered mouse models
exist, in which one of Myc, LIN28B, or Ctnnb1 oncogenes can be
induced in the mouse liver (Shachaf et al, 2004; Mokkapati et al,
2014; Nguyen et al, 2014) leading to HB or HCC development.
Based on our findings, we suggest concomitant oncogene activa-
tion and metabolic pathway alteration will enable to refine these
models to generate mice developing histologically defined subtypes
of HB. The elaboration of improved models could be useful for
preclinical trials aiming to identify better treatment strategies
against human HB.
The heterogeneity of HB tumors has enabled to classify them
first based on histological criteria, followed by molecular signa-
tures. In our study, we demonstrated that different subtypes of HB
differ metabolically. Indeed, embryonal but not fetal HB tissues
express GLUT3 and LDHB proteins, while fetal HBs express G6PC
preferentially. Although they might not be readily usable in clinical
settings alone, these new potential biomarkers might help discrimi-
nate between different tumor subtypes as a complement to conven-
tional histopathology. We hope that future investigations will
enable the discovery of additional metabolic markers, whose
distinct expression in different components of HB could help for
clinical diagnosis. Finally, our study may open an avenue for new
strategies, based on metabolic vulnerabilities, to treat aggressive
HB.
Materials and Methods
Cell culture conditions
HB and HCC cell lines were kindly provided by J. Gouttenoire and
D. Moradpour (University of Lausanne). HB cell lines Hep-U2 and
Hep293TT were from Dr. S. Bru¨derlein (University of Ulm,
Germany) (Scheil et al, 2003) and Prof. GE Tomlinson (University
of Texas, San Antonio, TX) (Chen et al, 2009). Cells were cultured
in RPMI 1640 medium (ThermoFisher) with L-glutamine, supple-
mented with 10% heat-inactivated fetal bovine serum, 1% peni-
cillin/streptomycin, 1 mM sodium pyruvate (ThermoFisher). The
addition of 25 mM HEPES buffer was required for Hep293TT cell
culture.
ChIP-PCR
Chromatin was prepared from 107 HB cells crosslinked with 4%
PFA as previously described (Rowe et al, 2013). Chromatin was
fragmented using a Covaris sonicator and immunoprecipitated using
the following antibodies: anti-TCF4 (Millipore, #05-511) or anti-b-
catenin (Abcam, ab32572). DNA was reverse-crosslinked O/N at
65°C by adding proteinase K (Promega) and RNAse A (Sigma-
Aldrich), purified using the Mini Elute PCR Purification Kit (Qia-
gen), and subjected to real-time PCR. Enrichment was calculated as
total input percentage (% TI). The following primers were used:
F4_for ACATCGGTGCTGCCACCTAC, F4_rev GGTTGGTGGAAGAA
CAGAC; F4c_for GGAAGGAAATGATCCCTAAT, F4c_rev GGTTG
GTGGAAGAACAGAC; Prom_for GGGATTACAAGTGTGAGCCACC,
Prom_rev TGAAGAATCACCAGCTTCTTGG; 50 Myc_for GCCTCACA
AAGTGCTAGGATTA, 50 Myc_rev CGGCCTCACAGAACAGAATAG.
Glucose uptake measurement
Briefly, cells were seeded the day before the experiment. All buffers,
except the one used for lysis, were freshly prepared. Cells were
washed 3× with 37°C wash buffer (2 mM pyruvic acid in Krebs–
Henseleit buffer: 1.18 mM KH2PO4, 1.18 mM MgSO4.7H2O, 2.5 mM
CaCl2.2H2O, 20 mM HEPES, 137 mM NaCl, 4.7 mM KCl) and
exposed to 37°C background buffer (50 mM D-glucose, 100 lM
2-DG, 1 lCi/ml 2-[2,6 3H]DG in PBS) or 37°C transport buffer
(100 lM 2-DG, 1 lCi/ml 2-[2,6 3H]DG in wash buffer). 10 min after
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start of exposure, transport was arrested with addition of stop buffer
(50 mM D-glucose in PBS 1×). Three washes using stop buffer were
made prior to lysis 100 mM NaOH, 0.1% SDS). Technical duplicate
samples were made, in addition to two samples used for normaliz-
ing containing 30 ll of either background or transport buffer
completed with 170 ll of lysis buffer. Following addition scintilla-
tion liquid to each sample, radioactivity was determined by scintilla-
tion counting. For sample normalization, protein concentration was
measured by BCA protein assay. Specific transport was calculated
by subtracting background well values to the corresponding trans-
port values.
Seahorse analysis
OCR and ECAR measurements were performed using the XF24 or
XF96 Extracellular Flux analyzer (Seahorse Bioscience, North
Billerica, MA). Briefly, cells were plated into XF96 (V3) poly-
styrene cell culture plates (Seahorse Bioscience, North Billerica).
The cells were incubated for 24–28 h in a humidified 37°C incuba-
tor with 5% CO2 (RMPI1640 medium). Prior to assay, cells were
incubated in a 37°C/non-CO2 incubator for 60 min. All experi-
ments were performed at 37°C. Each measurement cycle consisted
of a mixing time of 3 min and a data acquisition period of 2 min.
Each measurement was taken in triplicates. For glycolysis assay,
10 mM glucose was added during seahorse experiment followed
by 50 mM 2-DG after 24 h in RPMI medium without glucose
complemented with 5% serum. Palmitate–BSA consumption was
performed using the Seahorse XF Palmitate–BSA FAO Substrate
(Agilent) using the manufacturer’s instructions. OCR and ECAR
data points refer to the average rates during the measurement
cycles. Because the cell lines proliferate at different rates during
the 24- to 28-h incubation period, proteins were extracted using
RIPA buffer to determine protein concentration in each well after
an assay. OCR and ECAR were reported as normalized against
protein concentration.
Statistics
Unless specified differently, P-values were determined by Mann–
Whitney tests.
Data availability
The RNA sequencing data from this publication have been deposited
to the GEO database (https://www.ncbi.nlm.nih.gov/geo/) and
assigned the identifier: GSE83518.
Expanded View for this article is available online.
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